Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q1 FY26 results · Apr–Jun 2025
Lincoln Pharmaceuticals reported revenue from operations of ₹154.07 crore (up 4.6% from Q1 FY25) and net profit of ₹27.68 crore (up 16.9% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 154.07 | 147.28 | +4.6% | 168.18 | −8.4% |
| Other income | 15.27 | 10.41 | +46.7% | (6.88) | Turned profit |
| Total income | 169.34 | 157.69 | +7.4% | 161.30 | +5.0% |
| Profit before tax | 35.39 | 29.48 | +20.1% | 16.25 | +117.8% |
| Net profit for the period | 27.68 | 23.67 | +16.9% | 11.57 | +139.1% |
| EPS, basic (₹) | 13.82 | 11.82 | +16.9% | 5.78 | +139.1% |
| Net margin (%) | 18.0 | 16.1 | 6.9 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 154.07 | 147.28 | +4.6% | 168.18 | −8.4% |
| Other income | 15.27 | 10.41 | +46.7% | (6.88) | Turned profit |
| Total income | 169.34 | 157.69 | +7.4% | 161.30 | +5.0% |
| Profit before tax | 35.39 | 29.48 | +20.1% | 16.25 | +117.8% |
| Net profit for the period | 27.68 | 23.67 | +16.9% | 11.57 | +139.1% |
| EPS, basic (₹) | 13.82 | 11.82 | +16.9% | 5.78 | +139.1% |
| Net margin (%) | 18.0 | 16.1 | 6.9 |
Consolidated
- Filed with BSE
- 07 Aug 2025, 15:19 IST
- Board meeting
- 07 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Aug 2025, 15:19 IST
- Board meeting
- 07 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE